6C
683 Capital Management, LLC
13F filer · CIK 0001404574Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.04BU.S. long equity reported on 13F
Positions12317 new · 96 closed
Net flow last quarter-$151MBuys minus sells
Top 10 positions weight20.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026123 positions | |||||
| $73.2M | 3.60% | 0.06% | -2.7% | Q2 2016 | |
| $49.4M | 2.42% | Not reported | -3.2% | Q3 2017 | |
| $44.6M | 2.19% | 2.27% | -29.6% | Q1 2025 | |
| $40.7M | 2.00% | 0.25% | -1.1% | Q4 2025 | |
| $37.8M | 1.86% | 0.09% | +11.1% | Q4 2025 | |
| $37.7M | 1.85% | 0.32% | +3.1% | Q3 2025 | |
| $36.1M | 1.77% | 0.88% | -11.0% | Q3 2022 | |
| $35.5M | 1.75% | 0.45% | -18.3% | Q4 2022 | |
| $31.1M | 1.53% | 2.44% | -6.1% | Q3 2018 | |
| $28.8M | 1.41% | 2.56% | +1.0% | Q2 2021 | |
| $26.5M | 1.30% | 0.83% | +15.0% | Q4 2016 | |
| $23M | 1.13% | 1.15% | -16.4% | Q1 2022 | |
| $22.7M | 1.12% | 0.45% | +41.9% | Q4 2024 | |
| $21.4M | 1.05% | 0.25% | -34.1% | Q3 2018 | |
| $20.1M | 0.99% | 2.31% | Not reported | Q4 2021 | |
| $17.6M | 0.86% | 0.14% | New | Q2 2026 | |
| $16.4M | 0.81% | 0.18% | -11.1% | Q2 2023 | |
| $16M | 0.79% | 0.17% | -3.8% | Q1 2020 | |
| $15.5M | 0.76% | 0.02% | Not reported | Q1 2025 | |
| $15.1M | 0.74% | 2.12% | New | Q2 2026 | |
| $15M | 0.74% | 4.42% | +1.7% | Q1 2023 | |
| $14.1M | 0.69% | 0.74% | +4.3% | Q2 2023 | |
| $13.3M | 0.65% | 0.00% | Not reported | Q1 2025 | |
| $12.9M | 0.64% | 0.08% | Not reported | Q3 2023 | |
| $12.5M | 0.61% | 0.00% | -2.8% | Q4 2022 | |
| $12.3M | 0.60% | 1.44% | -12.3% | Q4 2023 | |
| $11.9M | 0.59% | 0.07% | -3.8% | Q1 2026 | |
| $11.5M | 0.56% | 0.37% | -3.8% | Q3 2023 | |
| $11.3M | 0.56% | 7.01% | +52.8% | Q2 2023 | |
| $11.3M | 0.55% | Not reported | +6.6% | Q1 2026 | |
| $10.9M | 0.54% | 0.19% | -57.0% | Q2 2024 | |
| $10.7M | 0.53% | 0.51% | Not reported | Q1 2023 | |
| $10.5M | 0.52% | 0.03% | +66.7% | Q3 2016 | |
| $10M | 0.49% | Not reported | New | Q2 2026 | |
| $10M | 0.49% | 0.23% | +294.4% | Q2 2024 | |
| $9.75M | 0.48% | 0.38% | -70.0% | Q1 2026 | |
| $9.63M | 0.47% | 0.16% | Not reported | Q4 2014 | |
| $9.08M | 0.45% | 0.38% | -4.0% | Q2 2017 | |
| $9.05M | 0.44% | Not reported | +1900.0% | Q1 2022 | |
| $8.89M | 0.44% | 0.01% | -39.5% | Q2 2025 | |
| $8.73M | 0.43% | 2.38% | +56.3% | Q3 2025 | |
| $8.47M | 0.42% | 0.69% | +10.2% | Q2 2025 | |
| $8.34M | 0.41% | 0.06% | -22.6% | Q1 2026 | |
| $8.05M | 0.40% | 0.08% | +12.5% | Q3 2022 | |
| $8.03M | 0.39% | 1.15% | +44.7% | Q4 2023 | |
| $6.79M | 0.33% | 0.34% | +43.5% | Q1 2026 | |
| $6.77M | 0.33% | 2.16% | +97.0% | Q1 2020 | |
| $6.53M | 0.32% | 0.11% | +16.7% | Q4 2022 | |
| $6.45M | 0.32% | 8.02% | +684.0% | Q3 2023 | |
| $6.43M | 0.32% | 2.87% | Not reported | Q3 2025 | |
| Q1 2026Reported May 15, 2026202 positions | |||||
| $68.4M | 3.57% | 0.06% | +11.9% | Q2 2016 | |
| $48.7M | 2.54% | Not reported | +3.3% | Q3 2017 | |
| $37.4M | 1.95% | 0.55% | -6.7% | Q4 2022 | |
| $35.5M | 1.85% | 2.55% | +22.0% | Q2 2021 | |
| $35.4M | 1.85% | 0.08% | +150.0% | Q4 2025 | |
| $35.2M | 1.84% | 0.25% | +79.3% | Q4 2025 | |
| $34.7M | 1.81% | 2.15% | -3.6% | Q1 2025 | |
| $30.3M | 1.58% | 0.96% | +4.0% | Q3 2022 | |
| $25.9M | 1.35% | 0.43% | -27.0% | Q2 2024 | |
| $21.3M | 1.11% | 0.31% | +18.5% | Q3 2025 | |
| $21.3M | 1.11% | 1.38% | -7.3% | Q1 2022 | |
| $21.2M | 1.11% | 3.01% | -4.3% | Q3 2018 | |
| $20.6M | 1.07% | 2.33% | +3.6% | Q4 2021 | |
| $20.2M | 1.05% | 0.32% | -7.2% | Q4 2024 | |
| $19.8M | 1.03% | 0.18% | +16.7% | Q1 2020 | |
| $19.6M | 1.02% | 0.39% | +63.9% | Q3 2018 | |
| $17.2M | 0.90% | 1.26% | New | Q1 2026 | |
| $16.3M | 0.85% | 0.71% | -7.4% | Q2 2023 | |
| $16.3M | 0.85% | 0.02% | Not reported | Q2 2025 | |
| $15.9M | 0.83% | 0.20% | +125.0% | Q2 2023 | |
| $14.9M | 0.78% | 4.35% | +1.4% | Q1 2023 | |
| $14.9M | 0.78% | 0.39% | -11.1% | Q3 2023 | |
| $13.8M | 0.72% | 0.00% | Not reported | Q1 2025 | |
| $11.7M | 0.61% | 0.02% | -4.8% | Q1 2025 | |
| $11.5M | 0.60% | Not reported | New | Q1 2026 | |
| $11.4M | 0.59% | 0.40% | +25.0% | Q2 2017 | |
| ATFOLDAmicus Therapeutics, Inc. | $11.2M | 0.58% | 0.25% | -3.1% | Q1 2025 |
| $11.1M | 0.58% | 0.08% | New | Q1 2026 | |
| $10.4M | 0.54% | 0.00% | Not reported | Q4 2022 | |
| APAPLSApellis Pharmaceuticals, Inc. | $10.1M | 0.52% | 0.20% | -24.2% | Q4 2022 |
| $9.67M | 0.50% | Not reported | Not reported | Q1 2022 | |
| $9.26M | 0.48% | 0.01% | New | Q1 2026 | |
| $9.09M | 0.47% | 1.65% | +7.7% | Q4 2023 | |
| $8.72M | 0.46% | 0.63% | Not reported | Q2 2025 | |
| $8.66M | 0.45% | 0.00% | -28.9% | Q1 2025 | |
| $8.48M | 0.44% | 0.90% | -25.0% | Q1 2024 | |
| $8.17M | 0.43% | 0.79% | +29.9% | Q4 2016 | |
| $7.48M | 0.39% | 3.93% | -1.2% | Q4 2016 | |
| $7.36M | 0.38% | 0.09% | +361.5% | Q4 2022 | |
| $6.95M | 0.36% | 0.02% | +455.3% | Q3 2016 | |
| $6.89M | 0.36% | 1.62% | +7.1% | Q3 2025 | |
| $6.88M | 0.36% | 2.88% | -4.5% | Q3 2025 | |
| $6.86M | 0.36% | 0.08% | New | Q1 2026 | |
| $6.59M | 0.34% | 0.07% | +122.2% | Q3 2022 | |
| $6.51M | 0.34% | 0.08% | -16.2% | Q3 2018 | |
| $6.16M | 0.32% | 6.31% | -12.3% | Q2 2024 | |
| $5.9M | 0.31% | 1.03% | New | Q1 2026 | |
| $5.54M | 0.29% | 1.06% | Not reported | Q4 2015 | |
| $5.52M | 0.29% | 0.00% | Not reported | Q1 2020 | |
| $5.46M | 0.29% | 0.02% | Not reported | Q3 2016 | |
| Q4 2025Reported Feb 17, 2026200 positions | |||||
| $81.2M | 3.53% | 0.05% | +3.1% | Q2 2016 | |
| $68.3M | 2.97% | 2.14% | -3.3% | Q2 2021 | |
| $63.3M | 2.75% | Not reported | Not reported | Q3 2017 | |
| $36.1M | 1.57% | 0.60% | -11.6% | Q2 2024 | |
| $33.3M | 1.45% | 0.90% | +19.2% | Q3 2022 | |
| $33.2M | 1.45% | 0.61% | -6.6% | Q4 2022 | |
| $31.4M | 1.37% | 2.31% | +18.5% | Q1 2025 | |
| $30.9M | 1.34% | 6.84% | -4.7% | Q2 2025 | |
| $29.6M | 1.29% | 2.50% | -1.9% | Q4 2021 | |
| $24.7M | 1.07% | 0.04% | -57.7% | Q4 2024 | |
| $24.2M | 1.05% | 0.34% | -34.5% | Q4 2024 | |
| $23.4M | 1.02% | 0.26% | +66.7% | Q3 2025 | |
| $20.7M | 0.90% | 0.14% | New | Q4 2025 | |
| $20.3M | 0.89% | 3.15% | -2.5% | Q3 2018 | |
| $19.9M | 0.87% | 1.50% | -6.3% | Q1 2022 | |
| $17.5M | 0.76% | 0.03% | New | Q4 2025 | |
| $17.4M | 0.76% | 0.77% | -18.2% | Q2 2023 | |
| $17.4M | 0.76% | 0.02% | -46.7% | Q2 2025 | |
| $16.1M | 0.70% | 2.22% | +2.6% | Q3 2023 | |
| $15.5M | 0.68% | 0.72% | +47.2% | Q1 2023 | |
| $15.1M | 0.66% | 4.29% | 0.0% | Q1 2023 | |
| $14.9M | 0.65% | 0.01% | -6.3% | Q1 2025 | |
| $14.8M | 0.65% | 0.15% | Not reported | Q1 2020 | |
| $14.7M | 0.64% | 0.02% | +133.3% | Q1 2025 | |
| $14.6M | 0.64% | 0.44% | Not reported | Q3 2023 | |
| $13.3M | 0.58% | 3.94% | +30.1% | Q1 2024 | |
| $12.9M | 0.56% | 1.20% | -7.7% | Q1 2024 | |
| $11.6M | 0.50% | Not reported | New | Q4 2025 | |
| ATFOLDAmicus Therapeutics, Inc. | $11.4M | 0.50% | 0.26% | -4.2% | Q1 2025 |
| $11.3M | 0.49% | 0.00% | Not reported | Q4 2022 | |
| $11.1M | 0.48% | 1.53% | +21.4% | Q3 2025 | |
| $10.9M | 0.48% | Not reported | Not reported | Q1 2022 | |
| $10.7M | 0.47% | 0.23% | +10.8% | Q3 2018 | |
| $9.93M | 0.43% | 3.95% | -5.7% | Q4 2016 | |
| VBVTYXVentyx Biosciences, Inc. | $9.39M | 0.41% | 1.46% | +4.0% | Q4 2023 |
| $9.21M | 0.40% | 0.62% | -64.0% | Q4 2016 | |
| $8.41M | 0.37% | 0.09% | Not reported | Q2 2023 | |
| $8.35M | 0.36% | 7.19% | +28.2% | Q2 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $8.29M | 0.36% | 0.26% | +14.6% | Q4 2022 |
| $8.11M | 0.35% | 1.59% | -7.2% | Q4 2023 | |
| $7.93M | 0.34% | 0.10% | New | Q4 2025 | |
| $7.93M | 0.34% | 2.54% | +86.6% | Q2 2017 | |
| $7.8M | 0.34% | 0.18% | New | Q4 2025 | |
| $7.16M | 0.31% | 1.03% | -54.0% | Q4 2021 | |
| $7.14M | 0.31% | 0.09% | -2.5% | Q3 2018 | |
| $6.92M | 0.30% | 0.32% | Not reported | Q2 2017 | |
| $6.81M | 0.30% | 0.64% | +6.1% | Q2 2025 | |
| $6.73M | 0.29% | Not reported | -17.1% | Q1 2022 | |
| $6.41M | 0.28% | 0.49% | -29.8% | Q1 2015 | |
| $6.4M | 0.28% | 0.16% | -24.2% | Q4 2022 | |
| Q3 2025Reported Nov 14, 2025111 positions | |||||
| $69.1M | 3.61% | 0.05% | +1.1% | Q2 2016 | |
| $62.5M | 3.26% | 1.72% | -16.7% | Q4 2016 | |
| $56.6M | 2.96% | Not reported | -3.2% | Q3 2017 | |
| $45.1M | 2.35% | 7.18% | +54.2% | Q2 2025 | |
| $41M | 2.14% | 0.68% | -17.6% | Q2 2024 | |
| $40.7M | 2.13% | 0.10% | Not reported | Q4 2024 | |
| $30.5M | 1.60% | 0.52% | -21.8% | Q4 2024 | |
| $30.4M | 1.59% | 2.59% | +1.2% | Q2 2021 | |
| $27.1M | 1.41% | 0.65% | -8.4% | Q4 2022 | |
| $26.1M | 1.37% | 0.72% | -19.4% | Q3 2022 | |
| $24.9M | 1.30% | 1.32% | +132.1% | Q1 2024 | |
| $24.6M | 1.28% | 0.04% | -45.5% | Q2 2025 | |
| $23.9M | 1.25% | 1.60% | -18.5% | Q1 2022 | |
| $21.6M | 1.13% | 3.26% | -2.4% | Q3 2018 | |
| $21.4M | 1.12% | 2.56% | -13.5% | Q4 2021 | |
| $19.1M | 1.00% | 0.94% | +46.7% | Q2 2023 | |
| $17.4M | 0.91% | 0.00% | +28.2% | Q1 2025 | |
| $16.7M | 0.88% | 1.98% | +9.4% | Q1 2025 | |
| $16.6M | 0.87% | 0.01% | -13.5% | Q1 2025 | |
| $15.6M | 0.81% | 0.16% | -29.4% | Q1 2024 | |
| $15.5M | 0.81% | 0.16% | New | Q3 2025 | |
| $13.8M | 0.72% | Not reported | Not reported | Q1 2022 | |
| $13.3M | 0.70% | 2.19% | -20.2% | Q3 2023 | |
| $12.9M | 0.67% | 4.29% | -7.9% | Q1 2023 | |
| $12.1M | 0.63% | 0.58% | -42.9% | Q1 2022 | |
| $11.9M | 0.62% | 0.07% | -19.7% | Q1 2025 | |
| $11.7M | 0.61% | 0.21% | Not reported | Q3 2018 | |
| $11.6M | 0.61% | 0.16% | +76.5% | Q1 2020 | |
| $10.6M | 0.56% | 0.00% | -24.9% | Q3 2024 | |
| $10.6M | 0.55% | 4.18% | -17.6% | Q4 2016 | |
| $10M | 0.52% | 0.61% | +12.1% | Q4 2022 | |
| $9.96M | 0.52% | Not reported | Not reported | Q1 2022 | |
| $9.27M | 0.48% | 1.73% | -13.3% | Q4 2023 | |
| $8.85M | 0.46% | 0.68% | -27.5% | Q1 2015 | |
| $8.82M | 0.46% | 0.53% | -40.0% | Q3 2023 | |
| $8.75M | 0.46% | 0.00% | Not reported | Q4 2022 | |
| $8.67M | 0.45% | 0.09% | -14.9% | Q2 2023 | |
| $7.77M | 0.41% | 0.49% | -6.6% | Q1 2023 | |
| $7.55M | 0.39% | 0.37% | Not reported | Q4 2020 | |
| $7.39M | 0.39% | 3.52% | +620.9% | Q1 2024 | |
| $6.93M | 0.36% | 2.94% | +105.2% | Q4 2021 | |
| $6.77M | 0.35% | 1.88% | Not reported | Q2 2025 | |
| ATFOLDAmicus Therapeutics, Inc. | $6.58M | 0.34% | 0.27% | -13.0% | Q1 2025 |
| APAPLSApellis Pharmaceuticals, Inc. | $6.52M | 0.34% | 0.23% | -29.8% | Q4 2022 |
| $6.32M | 0.33% | 0.61% | +98.9% | Q2 2025 | |
| $6.31M | 0.33% | 0.21% | -5.5% | Q4 2022 | |
| $6.13M | 0.32% | 1.68% | New | Q3 2025 | |
| $6.04M | 0.32% | 0.32% | -7.0% | Q2 2017 | |
| $5.82M | 0.30% | 0.00% | -5.4% | Q1 2020 | |
| $5.82M | 0.30% | 0.01% | -28.0% | Q1 2025 | |
Premium opens every quarter this fund has filed